Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting

INTRODUCTION: Non-cirrhotic treatment-naive hepatitis C patients infected with genotype 1 can be treated with ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks, but in practice this regimen is frequently extended up to 12 weeks at least in part due to insufficient real-world data supporting shortening of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zarębska-Michaluk, Dorota, Piekarska, Anna, Jaroszewicz, Jerzy, Klapaczyński, Jakub, Sitko, Marek, Tudrujek-Zdunek, Magdalena, Tomasiewicz, Krzysztof, Belica-Wdowik, Teresa, Pabjan, Paweł, Lorenc, Beata, Czauż-Andrzejuk, Agnieszka, Tronina, Olga, Krygier, Rafał, Dobracki, Witold, Buczyńska, Iwona, Simon, Krzysztof A., Dybowska, Dorota, Halota, Waldemar, Pawłowska, Małgorzata, Citko, Jolanta, Laurans, Łukasz, Mazur, Włodzimierz, Janczewska, Ewa, Socha, Łukasz, Deroń, Zbigniew, Berak, Hanna, Flisiak, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2019
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710286/
https://www.ncbi.nlm.nih.gov/pubmed/36457986
http://dx.doi.org/10.5114/aoms.2019.86569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710286/
https://www.ncbi.nlm.nih.gov/pubmed/36457986
http://dx.doi.org/10.5114/aoms.2019.86569

Ejemplares similares